Activists and 5% owners

Item 4, purpose of the transaction: Investment and company employee incentive awards

Item 4, purpose of the transaction: Investment purposes and Issuer employee incentive awards

Item 4, purpose of the transaction: The Reporting Persons are acquiring the Ordinary Shares in connection with a proposed business combination of the Issuer with Sports One ("Sports One"), a newly formed entity created by Paul Misir, Christopher Kelly and Reince Priebus. Sports One was formed to acquire and hold minority interests in professional sports teams, with a primary focus on the NBA, NFL, MLB and NHL, and to operate a sports intelligence business that provides real-time athlete-level data, social media value scoring, and quantified data for what each athlete is worth to sponsors. On August 31, 2026, the Issuer and Sports One announced that they have entered into a non-binding letter of intent (the "Letter of Intent"…

Item 4, purpose of the transaction: On September 3, 2026, the Issuer entered into a stock purchase agreement with Frank A. Selden, as trustee of the Gratitude 2022 Trust, to purchase 8,693,290 shares of Common Stock (the "Purchased Shares") from the Trust. The purchase of the Purchased Shares will close subject to the satisfaction or waiver of customary closing conditions, including the accuracy of the parties' respective representations and warranties and compliance with the parties' respective covenants, as well as the satisfactory receipt by the Issuer's transfer agent of a duly executed stock transfer power, bearing a medallion signature guarantee, evidencing the transfer of the Purchased Shared to the Issuer. The purchase…

Item 4, purpose of the transaction: The information set forth in Item 3 of this Schedule 13D is incorporated herein by reference. The Old Notes and New Notes were acquired for investment purposes. The shares of Common Stock beneficially owned by the Reporting Persons are held for general investment purposes. On December 26, 2024, Mr. O'Dowd adopted a Rule 10b5-1 trading arrangement (as such term is defined in Item 408(a) of Regulation S-K) (the "10b5-1 Plan"). The 10b5-1 Plan covers the purchase of $5,000 worth of shares of the Company's common stock per week, with no limit price. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is estimated to …

Item 4, purpose of the transaction: The Reporting Persons originally acquired the Common Stock reported herein for investment purposes because they believed such shares represented an attractive investment opportunity. The Reporting Persons intend to review their investments in the Issuer on a continuing basis and in connection with such review communicate with officers and directors of the Issuer or other stockholders or third parties, such as industry analysts, existing or potential strategic partners, investment professionals and other investors.

Item 4, purpose of the transaction: The securities reported herein were originally acquired on behalf of the Accounts in the ordinary course of the Investment Manager's business for investment purposes and, at the time of acquisition, without any purpose or effect of changing or influencing control of the Issuer. Accordingly, the Investment Manager previously reported its beneficial ownership on Schedule 13G pursuant to Rule 13d-1(b). As described more fully below, the Reporting Persons now hold the securities reported herein with a purpose or effect that may be deemed to relate to changing or influencing control of the Issuer, and this Schedule 13D is accordingly being filed pursuant to Rule 13d-1(e). On or about August 17, …

Item 4, purpose of the transaction: Item 3 of this Statement is incorporated herein by reference. The acquisitions by the Reporting Persons of the Issuer's securities as described herein were effected pursuant to the 2024 Subscription Agreement, the January 2025 Subscription Agreement and the October 2025 Subscription Agreement (collectively, the "Subscription Agreements"). The Reporting Persons acquired their securities for strategic investment purposes and in connection with (i) the purchase by Lantheus Holdings of all of the Issuer's rights to two licensed preclinical assets, a leucine-rich repeat-containing protein 15-targeted radiotherapeutic and a Trophoblast cell surface antigen-2-targeted radiodiagnostic on June 15, 2…

Item 4, purpose of the transaction: The Reporting Persons acquired the Class S Units reported herein for passive investment purposes and without the intent to effect any change in management or control of the Issuer. As of the date of this Schedule 13D, the Reporting Persons have no present plan or proposal that relates to or would result in any of the matters set forth in subsections (a) through (j) of this Item 4.

Item 4, purpose of the transaction: (a) N/A (b) BFNH and the Reporting Entity reserve the right to engage in the acquisition of other entities in the form of a merger or acquisition in the future; (c) BFNH and the Reporting Entity reserve the right to engage in the sale or transfer of a material amount of assets in the future; (d) No changes are forthcoming but the Conpany the reserves the right to change the management, the board and their terms in the future; (e) BFNH reserves the right to change the capital structure of the Company in the future. (f) N/A (g)N/A (h)N/A (i) N/A (jj) N/A

Item 4, purpose of the transaction: The Reporting Person acquired the Consideration Shares as consideration for the sale of PONM to the Issuer pursuant to the Purchase Agreement described in Item 3, and not by purchase for cash in the open market or otherwise. GLV and the Issuer are also parties to a Collaboration Agreement dated May 14, 2026 (the "Collaboration Agreement"), under which GLV provides the Issuer with operational, technical and strategic support relating to the continued development, compliance and commercialization of the Issuer's cranial electrotherapy stimulation technologies, in exchange for a fee of $10,000 per month over an initial term of 24 months. GLV entered into the Collaboration Agreement in its capa…

Item 4, purpose of the transaction: On June 9, 2026, our Sponsor paid $25,000 to cover certain offering costs in exchange for 2,156,250 ordinary shares (the "Founder Shares"). On July 6, 2026, our sponsor forfeited 431,250 Founder Shares. As a result, our sponsor currently holds 1,725,000 ordinary shares. On August 27, 2026, the Issuer consummated its initial public offering ("IPO") and in connection with the consummation of the IPO, Sponsor purchased an aggregate of 234,000 ordinary shares for an aggregate purchase price of $2,340,000. The reporting persons made the acquisitions reported in this Schedule 13D as sponsor and officer and director of the Issuer and in support of the Issuer's business plan. The reporting persons…

Item 4, purpose of the transaction: The information set forth in or incorporated by reference in Item 3 and Item 6 of this Schedule 13D is hereby incorporated by reference in its entirety into this Item 4. The Reporting Persons acquired the Ordinary Shares pursuant to the transactions contemplated by that certain Agreement and Plan of Merger, dated February 28, 2026 (as amended, restated, supplemented or otherwise modified from time to time, the "Business Combination Agreement") by and among Bleichroeder, Merger Sub, and Pasqal Holding SAS, a French societe par actions simplifiee (the "Legacy Pasqal"), the additional agreements contemplated therein, and the transactions contemplated therein and thereby, including the Reincorp…

Item 4, purpose of the transaction: The Reporting Person acquired the Units for investment purposes. The Reporting Person does not have any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D. The Reporting Person reserves the right to retain the normal flexibility of a significant stockholder to communicate with management and Issuer's Board of Directors regarding the Issuer and the Reporting Person's investment in the Issuer, acquire additional securities of the Issuer, exercise and/or convert securities held by the Reporting Person, vote his securities in the Issuer, and/or dispose of his securities in the Issuer, on such terms and at …

Item 4, purpose of the transaction: The Reporting Persons purchased the Shares based on the Reporting Persons' belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable. The Reporting Persons…

Item 4, purpose of the transaction: On August 24, 2026, the Issuer distributed to all holders of record of Shares as of 5:00 p.m., New York City time, on August 21, 2026 (the "Record Date") one transferable subscription right (each, a "Right") for each Share held as of the Record Date (the "Rights Offering"). Each Right entitles the holder thereof, subject to certain limitations, to purchase 3.885 Shares, rounded down to the nearest whole Share, at a subscription price of $1.49 per share (the "Subscription Price"); provided, that any holder that exercises its basic subscription rights in full will have an over-subscription privilege to purchase additional Shares that remain unsubscribed as of September 23, 2026 (the "Expiratio…

Item 4, purpose of the transaction: The Reporting Person acquired shares of Dynatrace Inc as part of its investment strategy, which includes considering the clarity and robustness of the issuer's long-term strategy; the functioning and calibre of governance structures and effective leadership; the financial strength and performance of issuers and the fair valuation of underlying securities; and financially-material sustainability risks & opportunities. The Reporting Person is therefore actively engaging with the Issuer to discuss and promote initiatives that align with these business practices. This engagement is part of the Reporting Person's broader strategy to support companies in enhancing their approach, thereby potentia…

Item 4, purpose of the transaction: Since February of 2022, the Reporting Person has filed a Statement of Beneficial Ownership on Schedule 13G and amendments thereto with respect to his beneficial ownership in the Issuer. As a result of the Proposal by the Advent Funds described below, which is premised on the Reporting Person's participation through a roll over arrangement, the Reporting Person is now converting his beneficial ownership filing on Schedule 13G to a filing on this Schedule 13D. On September 1, 2026, Advent International, L.P., on behalf of certain of its managed funds (the "Advent Funds"), submitted a preliminary non-binding indication of interest ("Proposal") to the Special Committee (the "Special Committee")…

Item 4, purpose of the transaction: Proposal On September 1, 2026, Advent LP, on behalf of the Advent GPE IX Funds (as defined herein) and the Advent Global Technology Funds (as defined herein) (collectively, the "Advent Funds") submitted a preliminary non-binding indication of interest ("Proposal") to the Special Committee (the "Special Committee") of the Board of Directors of the Issuer related to the proposed acquisition by the Advent Funds of all the outstanding shares of the Issuer's Common Stock and all of the outstanding limited liability company interests of AIDH TopCo, LLC (the "Definitive OpCo Units"), in each case, that are not already owned by the Advent Funds and Jason Krantz for an all-cash purchase price of $1.…

Item 4, purpose of the transaction: The Reporting Persons acquired the Class S Units reported herein for passive investment purposes and without the intent to effect any change in management or control of the Issuer. As of the date of this Schedule 13D, the Reporting Persons have no present plan or proposal that relates to or would result in any of the matters set forth in subsections (a) through (j) of this Item 4.

Item 4, purpose of the transaction: The Reporting Persons acquired the Class S Units reported herein for passive investment purposes and without the intent to effect any change in management or control of the Issuer. As of the date of this Schedule 13D, the Reporting Persons have no present plan or proposal that relates to or would result in any of the matters set forth in subsections (a) through (j) of this Item 4.

Item 4, purpose of the transaction: The Reporting Person acquired the Shares pursuant to a bona fide gift and not as part of any purchase transaction. The Reporting Person holds the Shares for investment purposes. The Reporting Person does not presently have any plans or proposals that relate to or would result in any of the actions described in clauses (a) through (j) of Item 4 of Schedule 13D.

Item 4, purpose of the transaction: On May 26, 2026, the Issuer issued 2,875,000 ordinary shares as founder shares to the Sponsor for an aggregate purchase price of $25,000. On August 25, 2026, the Sponsor transferred (i) 15,000 founder shares to Ally Tong Zhang, Chairwoman and Chief Executive Officer of the Issuer, (ii) 10,000 founder shares to Xin Wang, Chief Financial Officer of the Issuer, and (iii) 10,000 founder shares to each of Hongmei Zhao, Du Zhiqiang, and Wenhua Qian, independent directors of the Issuer. On August 27, 2026, simultaneously with the Issuer's initial public offering, the Sponsor acquired 205,800 private placement units in the private placement. Each private placement unit consists of one ordinary share…

Item 4, purpose of the transaction: The acquisition of securities of the issuer is part of a strategic collaboration as previously disclosed between Sermonix Pharmaceuticals, Inc. and the Issuer, as set forth in the previously disclosed License Agreement and Securities Purchase Agreement.

Item 4, purpose of the transaction: Business combination and acquisition.